Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EML4 | Q9HC35 | 14/20 | 0.82 |
| ▸ | ALK | Q9UM73 | 14/20 | 0.82 |
| ▸ | FLT3 | P36888 | 4/20 | 0.49 |
| ▸ | KIT | P10721 | 1/20 | 0.49 |
| ▸ | AXL | P30530 | 5/20 | 0.49 |
| ▸ | ETV6 | P41212 | 2/20 | 0.49 |
| ▸ | RET | P07949 | 3/20 | 0.48 |
| ▸ | ROS1 | P08922 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10129009 | 0.95 | EML4 (0.77) | EML4ALKFLT3KITAXL | |
| SCHEMBL10129007 | 0.95 | EML4 (0.77) | EML4ALKFLT3KITAXL | |
| SCHEMBL10129023 | 0.91 | EML4 (0.79) | EML4ALKFLT3AXLETV6 | |
| SCHEMBL10157468 | 0.91 | EML4 (0.85) | EML4ALKFLT3AXLETV6 | |
| SCHEMBL286514 | 0.90 | ALK (1.00) | EML4ALKFLT3RETROS1 | |
| SCHEMBL286515 | 0.90 | ALK (1.00) | EML4ALKFLT3RETROS1 | |
| SCHEMBL10128859 | 0.90 | ALK (0.86) | EML4ALKFLT3AXLETV6 | |
| SCHEMBL10128872 | 0.90 | ALK (0.86) | EML4ALKFLT3AXLETV6 | |
| SCHEMBL10128823 | 0.90 | ALK (1.00) | EML4ALKFLT3RETROS1 | |
| SCHEMBL10128578 | 0.89 | EML4 (0.82) | EML4ALKFLT3KITAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9487491-B2 | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC. (JP) | 2016-11-08 | — | — | US | disclosed |
| US-9487491-B2 | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC. (JP) | 2016-11-08 | — | — | US | disclosed |
| US-8969336-B2 | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC. (JP) | 2015-03-03 | — | — | US | disclosed |
| US-8969336-B2 | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC. (JP) | 2015-03-03 | — | — | US | disclosed |
| US-20140371196-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-12-18 | — | — | US | disclosed |
| US-20140371196-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-12-18 | — | — | US | disclosed |
| US-20120040968-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | WATERS TECHNOLOGIES CORPORATION (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040968-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | WATERS TECHNOLOGIES CORPORATION (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371196-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | EML4, ALK, ERBB4 | EML4 1/4885ALK 2/4885FLT3 5/4885 |
| US-20120040968-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | EML4, ALK, ERBB4 | EML4 1/4885ALK 2/4885FLT3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.